Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers: A case report

Pseudoprogression was reported as one of the unconventional responses during immune checkpoint inhibitor therapy. A 70‐year‐old man with pulmonary pleomorphic carcinoma received nivolumab therapy. Pleural effusion and pulmonary metastasis increased, however then shrank and serum cytokeratin 19 fragm...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Akihiro, Takumi, Chieko, Tsuji, Taisuke, Hamashima, Ryosuke, Shiotsu, Shinsuke, Yuba, Tatsuya, Urata, Yoji, Hiraoka, Noriya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028417/
https://www.ncbi.nlm.nih.gov/pubmed/29988633
http://dx.doi.org/10.1002/ccr3.1627
Descripción
Sumario:Pseudoprogression was reported as one of the unconventional responses during immune checkpoint inhibitor therapy. A 70‐year‐old man with pulmonary pleomorphic carcinoma received nivolumab therapy. Pleural effusion and pulmonary metastasis increased, however then shrank and serum cytokeratin 19 fragment levels decreased. Serum tumor marker might help to distinguish pseudoprogression.

Ejemplares similares